

Disclosures

Personal Commercial (14)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
35 Pharma	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
AOP Orphan	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Ferrer	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Gossamer	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Keros	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Liquida	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Respira	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Roivant	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
United Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/2/2024
URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/2/2024
URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/2/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.